Researchers call for CONSORT revision due to inconsistent Pfizer data

02/5/2013 | OutSourcing-Pharma.com

Researchers are seeking changes to journal publishing standards after they found that clinical trials reported by Pfizer for the seizure drug gabapentin didn't match up with internal reports of the drug studies. Professor Kay Dickersin of Johns Hopkins' Center for Clinical Trials said her team's findings indicate a need to revise the CONSORT statement, which provides a list of information that must be included when publishing trials.

View Full Article in:

OutSourcing-Pharma.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA